Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Connection

Mary Rinella to Clinical Trials as Topic

This is a "connection" page, showing publications Mary Rinella has written about Clinical Trials as Topic.

 
Connection Strength
 
 
 
0.856
 
  1. Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol. 2019 10; 71(4):823-833.
    View in: PubMed
    Score: 0.528
  2. Cheung A, Neuschwander-Tetri BA, Kleiner DE, Schabel E, Rinella M, Harrison S, Ratziu V, Sanyal AJ, Loomba R, Jeannin Megnien S, Torstenson R, Miller V. Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. Hepatology. 2019 11; 70(5):1841-1855.
    View in: PubMed
    Score: 0.135
  3. Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology. 2019 10; 70(4):1424-1436.
    View in: PubMed
    Score: 0.132
  4. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018 07; 24(7):908-922.
    View in: PubMed
    Score: 0.031
  5. Younossi ZM, Loomba R, Rinella ME, Bugianesi E, Marchesini G, Neuschwander-Tetri BA, Serfaty L, Negro F, Caldwell SH, Ratziu V, Corey KE, Friedman SL, Abdelmalek MF, Harrison SA, Sanyal AJ, Lavine JE, Mathurin P, Charlton MR, Chalasani NP, Anstee QM, Kowdley KV, George J, Goodman ZD, Lindor K. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology. 2018 07; 68(1):361-371.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.